APRE Aprea Therapeutics, Inc.
Company Updates ·
Aprea said it holds 28 issued and 30 pending patents for its precision oncology programs, with the WEE1 family of applications expiring in 2047 if granted.
Aprea Therapeutics reported a net loss of $3.6 million for the quarter ended June 30, 2026, and said its cash should last into the first quarter of 2028. The company is also expanding enrollment in its lead WEE1 inhibitor trial.
Aprea said its $30 million private placement closed on March 31, 2026, and reported $46.5 million in cash at March 31, 2026, with runway into the first quarter of 2028. The company also described two partial responses in its Phase 1 trial of APR-1051.
Aprea expects gross proceeds of approximately $5.6 million from selling 6,288,857 shares, or pre-funded warrants, with common warrants for the same number of shares at $0.765. Maxim Group LLC is placement agent for a 7% fee. Closing is expected January 30, 2026.
Aprea Therapeutics, Inc. describes itself as a clinical-stage precision medicine oncology company that develops small molecule inhibitors designed to exploit genetic mutations in cancer, using an approach called synthetic lethality. Its lead WEE1 inhibitor, APR-1051, is in a Phase 1 dose-escalation study, ACESOT-1051, which plans 9 cohorts evaluating doses of 10 mg to 300 mg once daily. The company announced unconfirmed partial responses in patients with PPP2R1A-mutated endometrial cancer. Its second clinical-stage program, ATRN-119, is an oral macrocyclic ATR inhibitor. The company determined a recommended Phase 2 dose of 1,100 mg once daily in a Phase 1/2a study, then paused enrollment in the monotherapy arms while it explores combinations, including with radiation in head and neck cancer. APR-1602, a DYRK1A/B inhibitor, is preclinical. The company acquired Atrin Pharmaceuticals Inc. in May 2022, and it has no ongoing clinical trials of its mutant p53 reactivator, APR-246.
| Product or program | What it is | Stage |
|---|---|---|
| APR-1051 | WEE1 inhibitor for biomarker-defined cancers | Phase 1 dose escalation |
| ATRN-119 (mosipasertib) | Oral macrocyclic ATR inhibitor for advanced solid tumors | Phase 1/2a; monotherapy enrollment paused |
| APR-1602 | Macrocyclic DYRK1A/B inhibitor | Preclinical |
| APR-246 (eprenetapopt) | Reactivator of mutant p53 | No ongoing clinical trials |
| Line | FY2025 | FY2024 |
|---|---|---|
| Net income (loss) | -$12.6 million | -$13.0 million |
| Cash from operations | -$12.9 million | -$13.6 million |
| Cash and equivalents | $14.6 million | $22.8 million |
Our latest story on this, dated May 13, 2026: "Aprea reports first-quarter 2026 results and $46.5 million in cash". The story links the filing or release it is based on. Read the story.
Aprea Therapeutics, Inc. trades under the ticker APRE on NASDAQ.
Aprea Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Aprea Therapeutics, Inc. is 1781983. Its filings are on SEC EDGAR.
12,591,136 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-12.
Our directory records Aprea Therapeutics, Inc. under United States.
Our directory classifies Aprea Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Aprea Therapeutics, Inc. is US03836J2015.
aibio.space lists Aprea Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Aprea Therapeutics, Inc. describes itself as a clinical-stage precision medicine oncology company that develops small molecule inhibitors designed to exploit genetic mutations in cancer, using an approach called synthetic lethality. Its lead WEE1 inhibitor, APR-1051, is in a Phase 1 dose-escalation study, ACESOT-1051, which plans 9 cohorts evaluating doses of 10 mg to 300 mg once daily.
APR-1051: WEE1 inhibitor for biomarker-defined cancers Stage: Phase 1 dose escalation.
ATRN-119 (mosipasertib): Oral macrocyclic ATR inhibitor for advanced solid tumors Stage: Phase 1/2a; monotherapy enrollment paused.
Aprea Therapeutics, Inc. reported a net loss of $12.6 million for the fiscal year ended Dec 31, 2025, and used $12.9 million of cash in operations, per its annual report to the SEC.
$41.2 million in cash at Jun 30, 2026, per its 10-Q.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio